Protara (TARA): Rasio kapitalisasi pasar marang pendapatan
Protara Therapeutics' development of drugs for rare oncological diseases is not subject to the influence of GDP or seasonality. The price-to-sales ratio visualizes the current market value, where determines the latest valuation metric. The future of the business relies on regulatory approval and therapy safety. The company's strategy is based on optimizing R&D expenses for the subsequent licensing of innovative cell therapies.
Rincian metrik lan analitis perusahaan Protara (TARA)
- rega saham lan prakiraan rega para ahli:
- data kapitalisasi bursa:
- indikator kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Protara Therapeutics|TARA - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Protara Tx|TARA - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Protara|TARA - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Protara Therapeutics|Rasio likuiditas perantara protaratx.com
- data bathi lan kelipatan valuasi:
TARA - Bathi resik|Penghasilan resik sing dikarepake Protara Therapeutics|TARA - Pangali P/E|Rasio prakiraan rega marang bathi Protara Therapeutics Inc|TARA - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Protara|TARA - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Protara Therapeutics|TARA - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan protaratx.com|TARA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Protara Therapeutics
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis umum perusahaan:TARA protaratx.com
By developing unique treatments for rare pathologies and oncology, Protara Therapeutics (TARA) is establishing a high-tech scientific hub where business value often outpaces current sales. The P/S multiple compares market capitalization to annual revenue, allowing GURU.Markets investors to determine, through P/S fluctuations, the extent of the premium paid for future revenue growth rates relative to the current asset valuation.
Karo sapa Protara Therapeutics saingan
ONC: Rasio rega marang dodolan|Rasio rega marang pendapatan Halozyme HALO|Rasio kapitalisasi pasar marang pendapatan RVMD|AAPG - Rasio rega marang pendapatan|Rega marang dodolan CG Oncology Therapeutics|URGN (UroGen Pharma Ltd.) - Kapitalisasi marang pendapatan|BCAX: Kapitalisasi marang volume dodolan|PSNL (Personalis) - Multiplikator P/S|Multiplikator P/S Erasca Inc|Rasio rega marang pendapatan Delcath (DCTH)|YMAB (Y-mAbs Corp) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S AURA (Aura Biosciences, Inc.)|Multiplikator P/S Candel Therapeutics Inc. CADL|ARAY: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|CTOR: Kapitalisasi marang volume dodolan|HURA (TuHURA Biosciences Inc.) - Multiplikator P/S|FATE: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S WHWK|TCRX - Rega marang dodolan|Rasio rega marang pendapatan Champions Oncology, Inc. CSBR|Rasio kapitalisasi pasar marang pendapatan XBIT|CEL-SCI Corp - Multiplikator P/S|OSTX - Multiplikator P/S|Radiopharm Theranostics (RADX) - Rasio rega marang pendapatan|Rasio rega marang dodolan ARTV (Artiva Biotherapeutics)|ANL (Adlai Nortye Ltd) - Multiplikator P/S|Rega marang dodolan Veru Corporation VERU|Kapitalisasi marang pendapatan TPST (Tempest Therapeutics)|Multiplikator P/S xiliotx.com (XLO)|Renovaro - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan MURA (Mural Oncology PLC)|Kairos Pharma Inc - Multiplikator P/S|Koefisien rega marang pendapatan OnKure Therapeutics Inc OKUR|GDTC: Multiplikator P/S|Kapitalisasi marang pendapatan Curis|Rasio rega marang pendapatan Apollomics Inc.|Tharimmune Inc (THAR) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan ADVB (Advanced Biomed Inc)|Kapitalisasi marang volume dodolan GNPX|Multiplikator P/S CLDI (Calidi Biotherapeutics, Inc.)|Multiplikator P/S sunshinebiopharma.com SBFM|XBIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SLRX (Salarius Pharmaceuticals Inc)|PPBT: Multiplikator P/S|American Oncology Network, Inc. (AONC) - Multiplikator P/S|BGNE (BeiGene, Ltd.) - Multiplikator P/S|Kapitalisasi marang pendapatan checkpointtx.com (CKPT)|Multiplikator P/S ELEV|Multiplikator P/S icadmed.com (ICAD)|Rasio rega marang pendapatan Ikena Oncology IKNA|NTBL: Rasio kapitalisasi marang pendapatan|Viracta - Multiplikator P/S|morphosys.com (MOR) - Kapitalisasi marang pendapatan|NAYA: Multiplikator P/S|Rega marang dodolan Ascentage Pharma Group International (AAPGV)
